![STAT+: ‘This is an industry that everyone [bleeping] hates’](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-1024x576.jpg?#)
.jpg)
Edgewise claims heart valve pressure benefits in phase 2 trial for potential Camzyos rival
Edgewise Therapeutics' hypertrophic cardiomyopathy asset has resulted in “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves.
Edgewise Therapeutics' hypertrophic cardiomyopathy asset has resulted in “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves.
